Back to top

Analyst Blog

Seattle Genetics, Inc. (SGEN - Snapshot Report) and partner Takeda Pharmaceuticals (TKPYY) recently reported results from a post-hoc analysis evaluating progression-free survival (PFS) in patients treated with Adcetris.

The post-hoc analysis was conducted on two pivotal phase II studies – one in patients with relapsed or refractory Hodgkin lymphoma (HL) post autologous stem cell transplant (ASCT) and the other in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

The post-hoc analysis from the phase II study conducted in patients with relapsed or refractory HL post-ASCT showed 62% of the patients achieved a longer PFS with Adcetris as compared with last prior therapy at a median follow-up of 27 months. Median PFS was 9.3 months with Adcetris as compared with 6.1 months in last prior therapy.

Twenty patients went through stem cell transplant (SCT) following Adcetris treatment. It was also noticed that 63% of the patients who relapsed within six months of last ASCT and 65% of the patients who relapsed within twelve months of last ASCT achieved a longer PFS with Adcetris as compared with last prior therapy.

The post-hoc analysis from the phase II study conducted in patients with relapsed or refractory sALCL showed 67% of the patients achieved a longer PFS with Adcetris as compared with last prior therapy at a median follow-up of 22 months. Median PFS was 19.6 months with Adcetris as compared with 5.9 months in last prior therapy. After Adcetris treatment, 20 patients went through SCT.

The data therefore revealed that Adcetris delayed disease progression when compared to prior therapies.

We note that Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of ASCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients. Adcetris generated $33.9 million of revenues in the first quarter of 2013.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now, Biogen Idec Inc. (BIIB - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
QIHOO 360 T… QIHU 95.04 +4.95%
PILGRIM'S P… PPC 31.52 +3.72%
CLAYTON WIL… CWEI 138.97 +3.55%
FLAMEL TECH… FLML 14.02 +3.16%
CALLON PETE… CPE 11.50 +3.14%